REFERENCES
1. Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2013;4:S265-88.
2. Le Rhun E, Galanis E. Leptomeningeal metastases of solid cancer. Curr Opin Neurol 2016;29:797-805.
3. Pan Z, Yang G, He H, Yuan T, Wang Y, et al. Leptomeningeal metastasis from solid tumors: clinical features and its diagnostic implication,. Sci Rep 2018;8:10445.
4. Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treat Rev 2017;53:128-37.
5. Lee Y, Han JY, Kim HT, Yun T, Lee GK, et al. Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. J Neurooncol 2013;115:95-101.
6. Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 2013;8:1570-3.
7. van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 2015;19:1-12.
8. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013;19:1584-96.
9. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32:1959-72.
10. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37:13-25.
11. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2:3-14.
12. Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell 2016;30:668-81.
13. Sprowls SA, Arsiwala TA, Bumgarner JR, Shah N, Lateef SS, et al. Improving CNS delivery to brain metastases by blood-tumor barrier disruption. Trends Cancer 2019;5:495-505.
14. Ota K, Shiraishi Y, Harada T, Himeji D, Kitazaki T, et al. Phase II study of erlotinib in advanced non-small cell lung cancer patients with leptomeningeal metastasis (LOGIK1101). J Thorac Oncol 2017;12:S271-2.
15. Tamiya A, Tamiya M, Nishihara T, Shiroyama T, Nakao K, et al. Efficacy and cerebrospinal fluid concentration of afatinib in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis. J Thorac Oncol 2017;12:S273.
16. Yang JC, Cho BC, Kim D, Kim SW, Lee JS, et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): updated results from the BLOOM study. Proc Am Soc Clin Oncol 2017;35:2020. (abstr)
17. Nanjo S, Hata A, Okuda C, Kaji R, Okada H, et al. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung. Br J Cancer 2018;118:32-7.
18. Ahn M, Kim D, Kim TM, Lin CC, Ratnayake J, et al. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). Proc Am Soc Clin Oncol 2016;34:9003. (abstr)
19. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-5.
20. Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 2015;16:e510-21.
21. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90.
22. Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 2014;74:1023-8.
23. Solomon B, Bauer TM, Felip E, Besse B, Philip L, et al. Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2016;34:9009. (abstr)
24. Demeule M, Régina A, Jodoin J, Laplante A, Dagenais C, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 2002;38:339-48.
25. Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol 2018;19:e43-55.
26. Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQM. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol 2017;19:1-24.
27. Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv 2016;13:963-75.
28. Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, et al. Phase 0 clinical trials: conceptions and misconceptions. Cancer J 2008;14:133-7.
29. Arbour KC, Kris MG, Riely GJ, Ni A, Beal K, et al. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer 2018;124:105-9.
30. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010;99:283-6.
31. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011;13:1364-9.
32. Wang S, Chen J, Xie Z, Xia L, Luo W, et al. Pulsatile crizotinib treatment for brain metastasis in a patient with non-small-cell lung cancer. J Clin Pharm Ther 2017;42:627-30.
33. Pellerino A, Bertero L, Rudà R, Soffietti R. Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. Ther Adv Neurol Disord 2018;11:1756286418759618.
34. Roelz R, Reinacher P, Jabbarli R, Kraeutle R, Hippchen B, et al. Surgical ventricular entry is a key risk factor for leptomeningeal metastasis of high grade gliomas. Sci Rep 2015;5:17758.
35. Ahn JH, Lee SH, Kim S, Shin SH, Gwak HS, et al. Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection. J Neurosurg 2012;116:984-93.
36. Ojerholm E, Lee JY, Thawani JP, Miller D, Alonso-Basanta M, et al. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis. J Neurosurg 2014;121:75-83.
37. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 2017;18:1040-8.
38. Foreman PM, Jackson BE, Singh KP, Romeo AK, Guthrie B, et al. Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal disease. J Clin Neurosci 2018;49:48-55.
39. Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 2017;168:1101-13.e13.
40. Conrad C, Dorzweiler K, Miller MA, Lauffenburger DA, Strik H, et al. Profiling of metalloprotease activities in cerebrospinal fluids of patients with neoplastic meningitis. Fluid Barriers CNS 2017;14:22.
41. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 2015;5:1164-77.
42. Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet 2020;52:371-7.
43. Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, et al. MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer cells. Mol Cancer Ther 2017;16:506-15.
44. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-501.
45. Ohara S, Ushijima T, Gunji I, Tanai C, Tanaka Y, et al. Brain metastasis effectively treated with erlotinib following the acquisition of resistance to gefitinib: a case report. J Med Case Rep 2014;8:64.
46. Fan Y, Hu M, Zhu X, Wang M, Xu Y, et al. Exploration of the underlying mechanisms of leptomeningeal metastasis in NSCLC patients through NGS of cerebrospinal fluid. J Thorac Oncol 2017;12:S271.
47. Jiang BY, Li Y, Chuai S, et al. NGS to reveal heterogeneity between cerebrospinal fluid and plasma ctDNA among non-small cell lung cancer patients with leptomeningeal carcinomatosis. Proc Am Soc Clin Oncol 2017;35:9022.
48. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumor harboring the T790M mutation. Clin Cancer Res 2011;17:1616-22.
49. Lombardi G, Zustovich F, Farina P, Puppa AD, Manara R, et al. Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. Oncologist 2011;16:1175-88.
50. Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, et al. The neurologic assessment in neuro-oncology (NANO) scale: a tool to assess neurologic function for integration into the response assessment in neuro-oncology (RANO) criteria. Neuro Oncol 2017;19:625-35.
51. Mason W. NANO, a practical scale for neurologic assessments in patients with brain tumors? Neuro Oncol 2017;19:603-4.
52. Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 2017;19:484-92.
53. Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, et al. Leptomeningeal metastasis: a response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol 2014;16:1176-85.
54. Singh SK, Leeds NE, Ginsber LE. MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol 2002;23:817-21.
55. Chamberlain MC. Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. CNS Oncol 2013;2:121-8.
56. Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, et al. The RANO leptomeningeal metastasis group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. Neuro Oncol 2019;21:648-58.
57. Le Rhun E, Weller M, Brandsma D, Van den B, de Azambuja H, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 2017;28:iv84-99.
58. Hyun JW, Jeong IH, Joung A, Cho HJ, Kim SH, et al. Leptomeningeal metastasis: clinical experience of 519 cases. Eur J Cancer 2016;56:107-14.
59. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-7.
60. Komori T, Delbeke D. Leptomeningeal carcinomatosis and intramedullary spinal cord metastases from lung cancer: detection with FDG positron emission tomography. Clin Nucl Med 2001;26:905-7.
61. Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013;8:185-91.
62. Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol 2019;21:571-84.
63. van Bussel MTJ, Pluim D, Milojkovic Kerklaan B, Bol M, Sikorska K, et al. Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. Neurology 2020;94:e521-8.
64. Jiang BY, Li YS, Guo WB, Zhang XC, Chen ZH, et al. Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells. Clin Cancer Res 2017;23:5480-8.
65. Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology 2013;80:1598-605.
66. Tu Q, Wu X, Le Rhun E, Blonski M, Wittwer B, et al. CellSearch technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis. Lung Cancer 2015;90:352-7.
67. Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, et al. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefinitib therapy failure. Respir Investig 2016;54:14-9.
68. Zheng MM, Li YS, Jiang BY, Tu HY, Tang WF, et al. Clinical utility of cerebrospinal fluid cell-free DNA as liquid biopsy for leptomeningeal metastases in ALK-rearranged NSCLC. J Thorac Oncol 2019;14:924-32.
69. Ying S, Ke H, Ding Y, Liu Y, Tang X, et al. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non small cell lung cancer patients with leptomeningeal metastases. Cancer Biol Ther 2019;20:562-70.
70. Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negativee populations. Cancer 2013;119:4325-32.
71. Zhao J, Ye X, Xu Y, Chen MJ, Zhong W, et al. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases. Cancer Chemother Pharmacol 2016;78:1305-10.
72. Huang R, Ge M, Zhou X, Ji X, Liao L, et al. Epidermal growth factor receptor mutation detection in cerebrospinal fluid of lung adenocarcinoma patients with leptomeningeal metastasis. Cancer Biother Radiopharm 2019;34:128-33.
73. Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung: a new medium of liquid biopsy. Ann Oncol 2018;29:945-52.
74. Ma C, Zhang J, Tang D, Ye X, Li J, et al. Tyrosine kinase inhibitors could be effective against non-small-cell lung cancer brain metastases harboring uncommon EGFR mutations. Front Oncol 2020;10:224.
75. Ma C, Yang X, Xing W, Yu H, Si T, et al. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples. Thorac Cancer 2020;11:588-93.
76. Nevel KS, DiStefano N, Lin X, Skakodub A, Ogilvie SQ, et al. A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer. Neuro Oncol 2020;22:675-83.
77. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 2010;136:1729-35.
78. Wolf A, Donahue B, Silverman JS, Chachoua A, Lee J K, et al. Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases. J Neurooncol 2017;134:139-43.
79. Gani C, Müller AC, Eckert F, Bender B, Pantazis G, et al. Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors. Strahlenther Onkol 2012;188:148-53.
80. Ozdemir Y, Yildirim BA, Topkan E. Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors. J Neurooncol 2016;129:329-35.
81. Brower JV, Saha S, Rosenberg SA, Hullett CR, Robins HI, et al. Management of leptomeningeal metastases: prognostic factors and associated outcomes. J Clin Neurosci 2016;27:130-7.
82. Hermann B, Hültenschmidt B, Sautter-Bihl ML. Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis. Strahlenther Onkol 2001;177:195-9.
83. Devecka M, Duma MN, Wilkens JJ, Kampfer S, Borm KJ, et al. Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting. BMC Cancer 2020;20:501.
84. Yang TJ, Wijetunga NA, Yamada J, Wolden S, Mehallow M, et al. Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro Oncol 2020;noaa152.
85. Central Nervous System Cancers: leptomeningeal Metastases (2020). v.2.2020. Available from: http://www.nccn.org. [Last accessed on 21 Oct 2020].
86. Montes de Oca Delgado M, Cacho Díaz B, Santos Zambrano J, Guerrero Juárez V, López Martínez M S, et al. The comparative treatment of intraventricular chemotherapy by ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis. Front Oncol 2018;8:509.
87. Zairi F, Le Rhun E, Bertrand N, Boulanger T, Taillibert S, et al. Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients,. J Neurooncol 2015;124:317-23.
88. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993;11:561-9.
89. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5:1655-62.
90. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5:3394-402.
91. Boogerd W, Hart AA, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991;67:1685-95.
92. Lin Y, Li H, Huang M, Guo A, Yin Z. Use of ommaya reservoirs to deliver pemetrexed in leptomeningeal metastasis from non-small cell lung cancer: a case report and review of the literature. Zhongguo Fei Ai Za Zhi 2019;22:546-50.
93. Wu YL, Zhou L, Lu Y. Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: a pooled analysis. Oncol Lett 2016;12:1301-14.
94. Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012;76:387-92.
95. Ariyasu R, Horiike A, Koyama J, Saiki M, Sonoda T, et al. Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib. Anticancer Drugs 2017;28:565-7.
96. Li Y S, Jiang BY, Yang JJ, Tu HY, Zhou Q, et al. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 2016;11:1962-9.
97. Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, et al. Treatment and survival of patients with EGFR-mutated non-small-cell cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer 2015;89:255-61.
98. Lee E, Keam B, Kim DW, Kim TM, Lee SH, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol 2013;8:1069-74.
99. Yang H, Yang X, Zhang Y, Liu X, Deng Q, et al. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib failure. Target Oncol 2015;10:135-40.
100. Kawamura T, Hata A, Takeshita J, Fujita S, Hayashi M, et al. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs. Cancer Chemother Pharmacol 2015;75:1261-6.
101. Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, et al. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget 2015;6:4527-36.
102. Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol 2015;10:1754-61.
103. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376:629-40.
104. Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the bloom study. J Clin Oncol 2020;38:538-47.
105. Saboundji K, Auliac JB, Perol M, François G, Janicot H, et al. Efficacy of osimertinib in EGFR mutated non-small-cell lung cancer with leptomeningeal metastases pretreated with EGFR tyrosine kinase inhibitors. Target Oncol 2018;13:501-7.
106. Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, et al. Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis. J Thorac Oncol 2020;15:637-48.
107. Park S, Lee MH, Seong M, Kim ST, Cho BC, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 2020;S0923-7534(20)39927-0.
108. Okuno T, Arakawa S, Yoshida T, Ohe Y. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation. Lung Cancer 2020;143:95-6.
109. Ahn MJ, Kim DW, Kim TM, Lin CC, Ratnayake J, et al. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). J Clin Oncol 2016;9003.
110. Cho BC, Ahn M, Lee J, Kim DW, Kim SW, et al. Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anticancer therapy. J Clin Oncol 2017;2069. (abstr)
111. Macias A, Neninger E, Santiesteban E, Boland W, Nicacio L, et al. 505 POSTER preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases. Eur J Cancer Suppl 2008;6:160-1.
112. Xu H, Zhou L, Lu Y, Su X, Cheng P, et al. Dual targeting of the epidermal growth factor receptor using combination of nimotuzumab and erlotinib in advanced non-small-cell lung cancer with leptomeningeal metastases: a report of three cases. Onco Targets Ther 2020;13:647-56.
113. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015;33:1881-8.
114. Ahn HK, Han B, Lee SJ, Lim T, Sun SM, et al. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. Lung Cancer 2012;76:253-4.
115. Crinò L, Ahn MJ, De Marinis F, Groen HJM, Wakelee H, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol 2016;34:2866-73.
116. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017;18:874-86.
117. Arrondeau J, Ammari S, Besse B, Soria JC. LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated non-small-cell lung cancer. J Thorac Oncol 2014;9:e62-3.
118. Dudnik E, Siegal T, Zach L, Allen AM, Flex D, et al. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. J Clin Neurosci 2016;26:46-9.
119. Chow LQ, Barlesi F, Bertino EM, Branle F, Shi M, et al. Results of the ASCEND-7 phase II study evaluating ALK inhibitor ceritinib in patients with ALK+ non-small cell lung cancer metastatic to the brain. ESMO Congress 2019. Abstract 1478O. Available from: https://www.annalsofoncology.org/article/S0923-7534(19)59686-7/fulltext. [Last accessed on 22 Oct 2020].
120. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017;390:29-39.
121. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377:829-38.
122. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 2015;10:232-6.
123. Ou SH, Sommers KR, Azada MC, Garon EB. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 2015;20:224-6.
124. Gainor JF, Chi AS, Logan J, Hu RL, Oh KS, et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol 2016;11:256-60.
125. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol 2016;17:1683-96.
126. Gaye E, Geier M, Bore P, Guilloïque M, Lucia F, et al. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis. Lung Cancer 2019;133:1-3.
127. Califano R, Hochmair MJ, Gridelli C, Delmonte A, Camidge DR. Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Ann Oncol 2019;30:ii41.
128. Pellerino A, Buffoni L, Rudà R, Soffietti R. Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors. Neurology 2019;93:217-9.
129. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
130. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
131. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50.
132. Barlesi F, Keunchil P, Ciardiello F, von Pawel J, Gadgeel S, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in advanced NSCLC. ESMO 2016;LBA44-PR.
133. Hulsbergen AFC, Mammi M, Nagtegaal SHJ, Lak AM, Kavouridis V, et al. Programmed death receptor ligand one expression may independently predict survival in patients with non-small cell lung carcinoma brain metastases receiving immunotherapy. Int J Radiat Oncol Biol Phys 2020;S0360-3016(20)31036-1.
134. Gion MRJ, Caramella C, Soria J, Soria JC, Besse B, et al. Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small celll lung cancer patient. Lung Cancer 2017;108:72-4.
135. Dudnik E, Yust-Katz S, Nechushtan H, Goldstein DA, Zer A, et al. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer 2016;98:114-7.
136. Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur J Cancer 2019;116:182-9.
137. Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, et al. Publisher correction: single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med 2020; doi: 10.1038/s41591-020-0978-1.
138. Salvador E, Shityakov S, Förster C. Glucocorticoids and endothelial cell barrier function. Cell Tissue Res 2014;355:597-605.
139. Bebawy JF. Perioperative steroids for peritumoral intracranial edema: a review of mechanisms, efficacy, and side effects. J Neurosurg Anesthesiol 2012;24:173-7.
140. Suzuki T, Sugimoto M, Koyama H, Mashimo T, Uchida I, et al. Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in xenopus oocytes. Anesthesiology 2004;101:660-5.
141. Ho CM, Ho ST, Wang JJ, Tsai SK, Chai CY. Dexamethasone has a central antiemetic mechanism in decerebrated cats. Anesth Analg 2004;99:734-9.
142. Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. Neurooncol Pract 2015;2:6-12.
